Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Krogsgaard

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|December 5, 2025
Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responsesRyan Curtin, Yogambigai Velmurugu, Fatoumatta Dibba, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Persistent Classical and Atypical Memory B Cells Underlie Heterogeneous Vaccine Responses in Ocrelizumab-Treated Multiple SclerosisRyan Curtin, Yogambigai Velmurugu, Fatoumatta Dibba, et al.
American Journal of Translational Research|December 8, 2009
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational researchLindsay G Wich, Heather K Hamilton, Richard L Shapiro, et al.
Oncoimmunology|December 21, 2023
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseasesPankti Reid, Sabina Sandigursky, Juhee Song, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
A pan-cancer atlas of therapeutic T cell targetsGuangyuan Li, Omar U Guzmán-Bringas, Aman Sharma, et al.
Annals of Clinical and Translational Neurology|May 7, 2024
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccinationIlya Kister, Ryan Curtin, Amanda L Piquet, et al.
Nature Communications|June 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicityYury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Nature Communications|July 27, 2023
Author Correction: Molecular mechanism of phosphopeptide neoantigen immunogenicityYury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint BlockadeIryna Voloshyna, Yury Patskovsky, Sabina Sandigursky, et al.
Nature|October 1, 2010
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligationHugo Mouquet, Johannes F Scheid, Markus J Zoller, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|December 5, 2025
Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responsesRyan Curtin, Yogambigai Velmurugu, Fatoumatta Dibba, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Persistent Classical and Atypical Memory B Cells Underlie Heterogeneous Vaccine Responses in Ocrelizumab-Treated Multiple SclerosisRyan Curtin, Yogambigai Velmurugu, Fatoumatta Dibba, et al.
American Journal of Translational Research|December 8, 2009
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational researchLindsay G Wich, Heather K Hamilton, Richard L Shapiro, et al.
Oncoimmunology|December 21, 2023
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseasesPankti Reid, Sabina Sandigursky, Juhee Song, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
A pan-cancer atlas of therapeutic T cell targetsGuangyuan Li, Omar U Guzmán-Bringas, Aman Sharma, et al.
Annals of Clinical and Translational Neurology|May 7, 2024
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccinationIlya Kister, Ryan Curtin, Amanda L Piquet, et al.
Nature Communications|June 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicityYury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Nature Communications|July 27, 2023
Author Correction: Molecular mechanism of phosphopeptide neoantigen immunogenicityYury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint BlockadeIryna Voloshyna, Yury Patskovsky, Sabina Sandigursky, et al.
Nature|October 1, 2010
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligationHugo Mouquet, Johannes F Scheid, Markus J Zoller, et al.
Pageof 7